Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Gourgou-Bourgade S, et al. Among authors: offersen bv. Ann Oncol. 2015 May;26(5):873-879. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Ann Oncol. 2015. PMID: 25725046 Free article. Review.
Through Clinicians Eyes: Use of an In-consultation Patient Decision Aid in Radiation Treatment for Early Breast Cancer. A Qualitative Study.
Søndergaard SR, Stie M, Bechmann T, Offersen BV, Nielsen MH, Møller M, Berry LL, Zachariae R, Steffensen KD, Lund L. Søndergaard SR, et al. Among authors: offersen bv. Clin Breast Cancer. 2024 Jun;24(4):e297-e309. doi: 10.1016/j.clbc.2024.02.009. Epub 2024 Feb 21. Clin Breast Cancer. 2024. PMID: 38523041 Free article.
Danish and Swedish National Data Collections for Cancer - Solutions for Radiotherapy.
Olsson CE, Krogh SL, Karlsson M, Eriksen JG, Björk-Eriksson T, Grau C, Norman D, Offersen BV, Nyholm T, Overgaard J, Zackrisson B, Hansen CR. Olsson CE, et al. Among authors: offersen bv. Clin Oncol (R Coll Radiol). 2025 Jan;37:103657. doi: 10.1016/j.clon.2024.10.009. Epub 2024 Oct 12. Clin Oncol (R Coll Radiol). 2025. PMID: 39522118 Review.
The Nordic Cardio-Oncology Society: mission and future goals.
Gulati G, Broberg AM, Offersen BV. Gulati G, et al. Among authors: offersen bv. Eur Heart J. 2024 Jun 1;45(21):1869-1871. doi: 10.1093/eurheartj/ehae014. Eur Heart J. 2024. PMID: 38607440 No abstract available.
Radiotherapy for breast cancer, the TARGIT-A trial.
Yarnold J, Offersen BV, Olivotto I, Poortmans P, Sarin R. Yarnold J, et al. Among authors: offersen bv. Lancet. 2014 May 17;383(9930):1717-8. doi: 10.1016/S0140-6736(14)60828-X. Lancet. 2014. PMID: 24835611 No abstract available.
Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time?
Kaidar-Person O, Poortmans P, Klimberg S, Haviland J, Offersen B, Audisio R, Yarnold J. Kaidar-Person O, et al. Breast Cancer Res Treat. 2014 Aug;147(1):221-2. doi: 10.1007/s10549-014-3032-5. Epub 2014 Jul 22. Breast Cancer Res Treat. 2014. PMID: 25048466 No abstract available.
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. Offersen BV, et al. Radiother Oncol. 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan 24. Radiother Oncol. 2015. PMID: 25630428
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Gourgou-Bourgade S, et al. Among authors: offersen bv. Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13. Ann Oncol. 2015. PMID: 26467471 Free article. No abstract available.
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. Offersen BV, et al. Radiother Oncol. 2016 Jan;118(1):205-8. doi: 10.1016/j.radonc.2015.12.027. Epub 2016 Jan 18. Radiother Oncol. 2016. PMID: 26791404 No abstract available.
160 results